<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC3902504</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC3902504.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">3902504</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">3902504</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">24448846</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1136/bmjopen-2013-003976</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">bmjopen-2013-003976</article-id></all-ids><extracted-table><table-id>BMJOPEN2013003976TB1</table-id><table-label>Table 1</table-label><table-caption>Demographics and clinical characteristics</table-caption><table-wrap-foot>The three groups did not differ regarding age, sex, years of education, cerebrovascular burden and Fazekas score.Numbers represent means±SD (range) unless otherwise indicated.*Significant at the p&lt;0.05 level.†Alzheimer's disease—mild cognitive impairment.‡Parkinson's disease.§Mini-Mental State Examination.¶Global Deterioration Scale, category 1=normal, category 2=subjective cognitive impairment, category 3=mild cognitive impairment.**Composite score from 0 to 6 were 0 indicates no cerebrovascular burden, 6 indicates a maximum disease burden.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="BMJOPEN2013003976TB1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographics and clinical characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">AD-MCI† (n=18)</th><th align="left" rowspan="1" colspan="1">PD‡ (n=18)</th><th align="left" rowspan="1" colspan="1">Controls (n=19)</th><th align="left" rowspan="1" colspan="1">p Valus*</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">65.6±5.6 (55–77)</td><td rowspan="1" colspan="1">66.7±5.1 (59–75)</td><td rowspan="1" colspan="1">64.6±6.5 (52–77)</td><td rowspan="1" colspan="1">0.537</td></tr><tr><td rowspan="1" colspan="1">Female sex, n</td><td rowspan="1" colspan="1">9 (50%)</td><td rowspan="1" colspan="1">9 (50%)</td><td rowspan="1" colspan="1">13 (68%)</td><td rowspan="1" colspan="1">0.424</td></tr><tr><td rowspan="1" colspan="1">Disease duration, years</td><td rowspan="1" colspan="1">2.4±1.7 (0.5–7)</td><td rowspan="1" colspan="1">2.2±1.1 (1–5)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">0.181</td></tr><tr><td rowspan="1" colspan="1">MMSE§ score</td><td rowspan="1" colspan="1">27.3±1.8 (24–30)</td><td rowspan="1" colspan="1">28.8±1.4 (26–30)</td><td rowspan="1" colspan="1">29.5±0.5 (29–30)</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td rowspan="1" colspan="1">GDS¶, categories 1/2/3, n</td><td rowspan="1" colspan="1">0/0/18</td><td rowspan="1" colspan="1">8/3/7</td><td rowspan="1" colspan="1">19/0/0</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td rowspan="1" colspan="1">Education, years</td><td rowspan="1" colspan="1">12.8±3.3 (8–18)</td><td rowspan="1" colspan="1">11.3±3.5 (7–18)</td><td rowspan="1" colspan="1">11.8±2.4 (8–16)</td><td rowspan="1" colspan="1">0.345</td></tr><tr><td rowspan="1" colspan="1">Fazekas; mean white matter score</td><td rowspan="1" colspan="1">1.0±0.8 (0–2)</td><td rowspan="1" colspan="1">0.9±0.7 (0–2)</td><td rowspan="1" colspan="1">0.8±0.6 (0–2)</td><td rowspan="1" colspan="1">0.779</td></tr><tr><td rowspan="1" colspan="1">Fazekas; mean periventricular score</td><td rowspan="1" colspan="1">1.1±0.5 (0–2)</td><td rowspan="1" colspan="1">1.1±0.5 (0–2)</td><td rowspan="1" colspan="1">1.1±0.5 (0–2)</td><td rowspan="1" colspan="1">0.927</td></tr><tr><td rowspan="1" colspan="1">Cerebrovascular composite score**</td><td rowspan="1" colspan="1">1.7±1.0 (0–3)</td><td rowspan="1" colspan="1">1.6±1.4 (0–4)</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">0.894</td></tr></tbody></table><table-wrap-foot><fn><p>The three groups did not differ regarding age, sex, years of education, cerebrovascular burden and Fazekas score.</p></fn><fn><p>Numbers represent means±SD (range) unless otherwise indicated.</p></fn><fn><p>*Significant at the p&lt;0.05 level.</p></fn><fn><p>†Alzheimer's disease—mild cognitive impairment.</p></fn><fn><p>‡Parkinson's disease.</p></fn><fn><p>§Mini-Mental State Examination.</p></fn><fn><p>¶Global Deterioration Scale, category 1=normal, category 2=subjective cognitive impairment, category 3=mild cognitive impairment.</p></fn><fn><p>**Composite score from 0 to 6 were 0 indicates no cerebrovascular burden, 6 indicates a maximum disease burden.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographics and clinical characteristics</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left">Variables</th><th align="left">AD-MCI† (n=18)</th><th align="left">PD‡ (n=18)</th><th align="left">Controls (n=19)</th><th align="left">p Valus*</th></tr></thead><tbody><tr><td>Age, years</td><td>65.6±5.6 (55–77)</td><td>66.7±5.1 (59–75)</td><td>64.6±6.5 (52–77)</td><td>0.537</td></tr><tr><td>Female sex, n</td><td>9 (50%)</td><td>9 (50%)</td><td>13 (68%)</td><td>0.424</td></tr><tr><td>Disease duration, years</td><td>2.4±1.7 (0.5–7)</td><td>2.2±1.1 (1–5)</td><td>–</td><td>0.181</td></tr><tr><td>MMSE§ score</td><td>27.3±1.8 (24–30)</td><td>28.8±1.4 (26–30)</td><td>29.5±0.5 (29–30)</td><td>0.000</td></tr><tr><td>GDS¶, categories 1/2/3, n</td><td>0/0/18</td><td>8/3/7</td><td>19/0/0</td><td>0.000</td></tr><tr><td>Education, years</td><td>12.8±3.3 (8–18)</td><td>11.3±3.5 (7–18)</td><td>11.8±2.4 (8–16)</td><td>0.345</td></tr><tr><td>Fazekas; mean white matter score</td><td>1.0±0.8 (0–2)</td><td>0.9±0.7 (0–2)</td><td>0.8±0.6 (0–2)</td><td>0.779</td></tr><tr><td>Fazekas; mean periventricular score</td><td>1.1±0.5 (0–2)</td><td>1.1±0.5 (0–2)</td><td>1.1±0.5 (0–2)</td><td>0.927</td></tr><tr><td>Cerebrovascular composite score**</td><td>1.7±1.0 (0–3)</td><td>1.6±1.4 (0–4)</td><td>–</td><td>0.894</td></tr></tbody></table></div>The three groups did not differ regarding age, sex, years of education, cerebrovascular burden and Fazekas score.Numbers represent means±SD (range) unless otherwise indicated.*Significant at the p&lt;0.05 level.†Alzheimer's disease—mild cognitive impairment.‡Parkinson's disease.§Mini-Mental State Examination.¶Global Deterioration Scale, category 1=normal, category 2=subjective cognitive impairment, category 3=mild cognitive impairment.**Composite score from 0 to 6 were 0 indicates no cerebrovascular burden, 6 indicates a maximum disease burden.</transformed-table></extracted-table></extracted-tables-set>